| 1 |
Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis [J]. Am J Kidney Dis, 2013, 62(3): 403-441.
|
| 2 |
Nakayama M, Katafuchi R, Yanase T, et al. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome [J]. Am J Kidney Dis, 2002, 39(3): 503-512.
|
| 3 |
Kidney Disease: Improving Global Outcome (KDIGO) Glomerulonephritis Work Group.KDIGO Clinical Practice Guideline for Glomerulonephritis [J]. Kidney Int Suppl, 2012, 2(2): 38-76.
|
| 4 |
Megrogan A, Franssen CF, De Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature [J]．Nephrol Dial Transplant, 2011, 26(2): 414-430.
|
| 5 |
Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study [J]. Circulation, 2008, 117(2): 224-230.
|
| 6 |
Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes [J]. Clin J Am Soc Nephrol, 2007, 2(3): 445-453.
|
| 7 |
Korbet SM. Treatment of primary focal segmental glomerulosclerosis [J]. Kidney Int, 2002, 62(6): 2301-2310.
|
| 8 |
Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations [J]. Kidney Int, 2007, 72(12): 1429-1447.
|
| 9 |
Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome [J]. Kidney Int, 1993, 43(6): 1377-1384.
|
| 10 |
Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group [J]. Kidney Int, 1999, 56(6): 2220-2226.
|
| 11 |
Meyrier A, Noel LH, Auriche P, et al. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie [J]. Kidney Int, 1994, 45(5): 1446-1456.
|
| 12 |
Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy [J]. Nephrol Dial Transplant, 2004, 19(12): 3062-3067.
|
| 13 |
Segarra A, Vila J, Pou L, et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up [J]. Nephrol Dial Transplant, 2002, 17(4): 655-662.
|
| 14 |
Polanco N, Gutierrez E, Covarsi A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy [J]. J Am Soc Nephrol, 2010, 21(4): 697-704.
|
| 15 |
Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment [J]. Clin J Am Soc Nephrol, 2008, 3(3): 905-919.
|
| 16 |
Laluck BJ Jr, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy [J]. Am J Kidney Dis, 1999, 33(6): 1026-1032.
|
| 17 |
Troyanov S, Wall CA, Miller JA, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission [J]. Kidney Int, 2004, 66(3): 1199-1205.
|
| 18 |
Shearman JD, Yin ZG, Aarons I, et al. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy [J]. Clin Nephrol, 1988, 30(6): 320-329.
|
| 19 |
Ponticelli C, Zucchelli P, Imbasciati E, et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy [J]. N Engl J Med, 1984, 310(15): 946-950.
|
| 20 |
Cattran DC. Idiopathic membranous glomerulonephritis [J]. Kidney Int, 2001, 59(5): 1983-1994.
|
| 21 |
Cattran DC, Greenwood C, Ritchie S, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group [J]. Kidney Int, 1995, 47(4): 1130-1135.
|
| 22 |
Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy [J]. Am J Kidney Dis, 2006, 47(2): 233-240.
|
| 23 |
Glassock RJ. Membranoproliferative glomerulonephritis [M] Ponticelli C, Glassock R. Treatment of primary glomerulonephritis. 2nd ed. Oxford: Oxford University Press, 2009: 375-398.
|
| 24 |
Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: a new therapeutic hope [J]. Nephrol Dial Transplant, 2008, 23(1): 11-17.
|
| 25 |
Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome [J]? Nephrol Dial Transplant, 2007, 22(7): 2100-2102.
|
| 26 |
Fernandez-Fresnedo G, Segarra A, González E, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis [J]. Clin J Am soc nephrol, 2009, 4(8): 1317-1328.
|
| 27 |
谢海英，李春华，何剑中，等．利妥昔单抗治疗难治性肾病综合征的Meta分析 [J]．中华肾脏病杂志，2013，29(10): 788-790.
|